CN112867480B - Oral care compositions comprising N-alkyl-N-acyl glucamines - Google Patents

Oral care compositions comprising N-alkyl-N-acyl glucamines Download PDF

Info

Publication number
CN112867480B
CN112867480B CN201880098740.XA CN201880098740A CN112867480B CN 112867480 B CN112867480 B CN 112867480B CN 201880098740 A CN201880098740 A CN 201880098740A CN 112867480 B CN112867480 B CN 112867480B
Authority
CN
China
Prior art keywords
oral care
care composition
alkyl
methyl
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880098740.XA
Other languages
Chinese (zh)
Other versions
CN112867480A (en
Inventor
阿拉德哈娜·达斯
沈宏伟
徐云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colgate Palmolive Co
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of CN112867480A publication Critical patent/CN112867480A/en
Application granted granted Critical
Publication of CN112867480B publication Critical patent/CN112867480B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oral care compositions and methods for the same are disclosed. The oral care composition may include an orally acceptable vehicle and one or more surfactants. The one or more surfactants may include N-alkyl-N-acyl glucamine. The oral care composition may further comprise an amino acid and one or more abrasives. Methods for treating or reducing dentinal hypersensitivity may include contacting the oral care composition with a tooth surface.

Description

Oral care compositions comprising N-alkyl-N-acyl glucamines
Background
Dentin or dentinal hypersensitivity is a common clinical condition associated with exposed dentinal surfaces of teeth. Dentin contains a large number of pores or dentinal tubules that extend from the outer surface of the tooth to the nerves within the tooth. Thus, exposure of dentin often results in increased sensitivity of the tooth to external stimuli (e.g., temperature, pressure, etc.). In view of the above, conventional oral care products or compositions thereof often may attempt to numb nerves or incorporate fillers or blocking agents to improve the sensitivity of the teeth. For example, conventional oral care compositions (e.g., colgate Sensitive ) Arginine and calcium carbonate are often included as a seal to block dentin and reduce sensitivityAnd (5) plugging agent.
While conventional oral care compositions have proven effective in reducing sensitivity, the active ingredients (e.g., arginine, calcium carbonate, etc.) often can react with one or more foaming agents in the oral care composition, thereby reducing the ability of the oral care composition to generate foam. For example, conventional oral care compositions primarily utilize anionic surfactants, such as sodium lauryl sulfate, as the primary foaming agent. However, anionic surfactants react with the calcium cations provided by the cationically charged arginine and calcium carbonate to produce insoluble salts, thereby reducing the usability of the foaming agent and its foaming ability.
There is a need, then, for improved desensitizing oral care compositions and methods therefor.
Disclosure of Invention
This summary is intended merely to introduce a simplified overview of some aspects of one or more embodiments of the present disclosure. Further areas of applicability of the present disclosure will become apparent from the detailed description provided hereinafter. This summary is not an extensive overview and is intended to neither identify key or critical elements of the teachings nor delineate the scope of the disclosure. Indeed, it is merely intended to provide a simplified form of one or more concepts as a prelude to the more detailed description that is presented later.
The foregoing and/or other aspects and utilities embodied in the present disclosure may be achieved by providing an oral care composition comprising an orally acceptable vehicle and one or more surfactants. The one or more surfactants may include N-alkyl-N-acyl glucamine.
In at least one embodiment, the oral care composition may further comprise an amino acid. In at least one embodiment, the amino acids may include one or more of the following: arginine, lysine, citrulline, ornithine, creatine, histidine, diaminobutyric acid, diaminopropionic acid, salts thereof, or combinations thereof. In at least one embodiment, the amino acid may comprise arginine, optionally, the arginine is provided by arginine bicarbonate, further optionally, the arginine is provided by an arginine bicarbonate solution.
In at least one embodiment, the oral care composition may further comprise an abrasive. In at least one embodiment, the abrasive may include one or more of the following: sodium metaphosphate, potassium metaphosphate, calcium pyrophosphate, magnesium orthophosphate, tricalcium phosphate, dicalcium phosphate dihydrate, anhydrous dicalcium phosphate, calcium carbonate, magnesium carbonate, hydrated alumina, silica, zirconium silicate, aluminum silicate, calcined aluminum silicate, polymethyl methacrylate or combinations thereof. In at least one embodiment, the abrasive can include calcium carbonate, optionally, the calcium carbonate can include natural calcium carbonate and/or precipitated calcium carbonate.
In at least one embodiment, the N-alkyl-N-acyl glucosamine can be represented by formula (I), as disclosed herein, wherein R a Can be straight or branched, saturated or unsaturated C 6 -C 22 Alkyl, or alkyl or mono-or polyunsaturated alkenyl, and wherein R b Is C 1 -C 4 An alkyl group. In at least one embodiment, the N-alkyl-N-acyl glucosamine may comprise N-methyl-N-acyl glucosamine. In at least one embodiment, the N-alkyl-N-acyl glucosamine may comprise N-methyl-N-C 8 -C 10 -acyl glucamine and/or N-methyl-N-C 12 -C 14 -acyl glucamine.
In at least one embodiment, the one or more surfactants may further comprise one or more anionic surfactants, one or more nonionic surfactants, one or more cationic surfactants, one or more amphoteric surfactants, one or more zwitterionic surfactants, or a combination thereof.
In at least one embodiment, the one or more surfactants may further comprise an anionic surfactant, optionally the anionic surfactant may comprise sodium N-methyl-N-alkyl taurate, optionally the sodium N-methyl-N-alkyl taurate may comprise sodium cocoyl methyl taurate and sodium lauroyl methyl taurate.
In at least one embodiment, the one or more surfactants may further include betaines and sulfobetaines, optionally, the betaines include cocamidopropyl betaine.
In at least one embodiment, the oral care composition may be free or substantially free of sodium lauryl sulfate.
In at least one embodiment, the oral care composition is a toothpaste.
The foregoing and/or other aspects and utilities embodied in the present disclosure may be achieved by providing a method for treating dentinal hypersensitivity in a human, which may include contacting any one or more of the oral care compositions disclosed herein with a surface of a tooth or a human body.
The foregoing and/or other aspects and utilities embodied in the present disclosure may be achieved by providing any one or more of the oral care compositions disclosed herein for treating dentinal hypersensitivity in a human.
The foregoing and/or other aspects and utilities embodied in the present disclosure can be achieved by providing a method of preparing an oral care composition having increased foam generation. The method may comprise combining an orally acceptable vehicle with at least one N-alkyl-N-acyl glucosamine and optionally at least one additional surfactant or foaming agent. The method may further comprise adding one or more amino acids and one or more abrasives to the orally acceptable vehicle and the at least one N-alkyl-N-acyl glucosamine.
Further areas of applicability of the present disclosure will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating some typical aspects of the disclosure, are intended for purposes of illustration only and are not intended to limit the scope of the disclosure.
Detailed Description
The following description of various exemplary aspects is merely exemplary in nature and is in no way intended to limit the disclosure, its application, or uses.
As used throughout this disclosure, ranges are used as shorthand expressions for describing each and every value that is within the range. It is to be understood and appreciated that the description in range format is merely for convenience and brevity and should not be construed as a inflexible limitation on the scope of any embodiments or implementations disclosed herein. Accordingly, the disclosed ranges are to be construed as having specifically disclosed all possible sub-ranges as well as individual values within the ranges. Thus, any value within the range can be selected as the terminus of the range. For example, descriptions of ranges such as 1 to 5 should be considered as having specifically disclosed sub-ranges such as 1.5 to 3, 1 to 4.5, 2 to 5, 3.1 to 5, etc., as well as individual numbers within the ranges, e.g., 1, 2, 3, 3.2, 4, 5, etc. This applies regardless of the width of the range.
All references cited herein are incorporated by reference in their entirety. If a definition in the present disclosure conflicts with a definition in a cited reference, the present disclosure controls.
All percentages and amounts expressed herein and elsewhere in this specification are to be understood as referring to weight percentages unless otherwise indicated.
In addition, all numerical values are "about" or "approximately" the stated value, and experimental errors and variations as would be expected by one of ordinary skill in the art are taken into account. It is to be understood that all numerical values and ranges disclosed herein are approximate values and ranges, whether or not "about" is used in conjunction therewith. It will also be understood that the term "about" in conjunction with a number, as used herein, refers to a value that may be + -0.01% (inclusive), + -0.1% (inclusive), + -0.5% (inclusive), + -1% (inclusive) of the number, + -2% (inclusive) of the number, + -3% (inclusive) of the number, + -5% (inclusive) of the number, + -10% (inclusive) of the number, or + -15% (inclusive) of the number. It should be further understood that when numerical ranges are disclosed herein, any number falling within the ranges are specifically disclosed.
The inventors have surprisingly and unexpectedly found that the use of N-alkyl-N-acyl glucamines, such as N-methyl-N-C 8 -C 10 -acyl glucamine and/or N-methyl-N-C 12 -C 14 Acyl glucamines, oral care compositions that are foaming agents exhibit relatively greater foam generation than conventional oral care compositions that include conventional surfactants such as sodium lauryl sulfate. It will be appreciated that oral care compositions comprising N-alkyl-N-acyl glucamines exhibit relatively greater foam generation at relatively lower concentrations, and that the generated foam is relatively denser, richer, and/or more creamy than foam generated from conventional oral care compositions comprising conventional surfactants. It has also been surprisingly and unexpectedly found that supplementing N-alkyl-N-acyl glucosamine with additional surfactant or foaming agent (whether active or inactive) further enhances foam generation in oral care compositions as compared to conventional oral care compositions.
Composition and method for producing the same
The compositions disclosed herein may be or include an oral care product or oral care composition thereof. For example, the compositions disclosed herein can be an oral care product or oral care composition thereof that includes an oral care composition. In at least one embodiment, the compositions disclosed herein can be or include an oral care composition comprising an orally acceptable vehicle or carrier and at least one N-alkyl-N-acyl glucosamine capable of or configured to provide relatively greater foam production as compared to conventional oral care compositions. For example, the compositions disclosed herein may be or include an oral care composition, such as a toothpaste composition for sensitive teeth, comprising an orally acceptable vehicle or carrier and at least one N-alkyl-N-acyl glucosamine, such as N-methyl-N-C, capable of or configured to provide relatively greater foam production as compared to conventional oral care compositions 8 -C 10 -acyl glucamine and/or N-methyl-N-C 12 -C 14 Acyl glucamines, the conventional oral care compositions utilize conventional cationically charged surfactants such as Sodium Lauryl Sulfate (SLS). In at least one embodiment, the oral care composition may include an orally acceptable vehicle or carrier, one or more N-alkyl-N-acyl groupsGlucosamine, one or more amino acids, and one or more abrasives. In another embodiment, the oral care composition may include an orally acceptable vehicle or carrier, one or more N-alkyl-N-acyl glucamines and at least one additional surfactant or foaming agent, one or more amino acids (e.g., arginine), and one or more abrasives (e.g., calcium carbonate).
Illustrative oral care products or compositions of the present disclosure may be or include, but are not limited to, toothpastes (dentifrices), prophylaxis pastes, tooth powders, or tooth gels (e.g., whitening gels). In exemplary embodiments, the oral care compositions disclosed herein can be a dentifrice or toothpaste. For example, the oral care compositions disclosed herein can be toothpastes for treating tooth sensitivity or dentinal hypersensitivity.
The oral care product or oral care composition thereof may be a single phase oral care product or a single phase oral care composition. For example, all components of an oral care product or oral care composition thereof may be held together in a single phase and/or a single container. For example, all components in an oral care product or oral care composition thereof may be maintained in a single phase, such as a single homogeneous phase. In another embodiment, the oral care product or oral care composition thereof may be a multi-phase oral care product or a multi-phase oral care composition.
The pre-use oral care product or oral care composition may have a "low water content". As used herein, "low water content" may refer to a composition containing water in an amount of greater than about 5 wt% and less than about 15 wt%, less than about 13 wt%, less than about 10 wt%, or less than about 7 wt%, based on the total weight of the oral care composition. In another embodiment, the oral care product or oral care composition thereof may be an anhydrous formulation or an anhydrous composition. For example, the oral care composition prior to use may be anhydrous, free of water, or substantially free of water. As used herein, "free of water" or "substantially free of water" may refer to a composition containing water in an amount of less than 5.0 wt%, less than 3.0 wt%, less than 1.0 wt%, less than 0.1 wt%, less than 0.05 wt%, less than 0.01 wt%, less than 0.005 wt%, or less than 0.0001 wt%, based on the total weight of the oral care composition.
Amino acids
The oral care composition may include one or more amino acids. One or more amino acids in the oral care composition may be in free or salt form. Illustrative amino acids that may be used in the oral care composition may include, but are not limited to, arginine, lysine, citrulline, ornithine, creatine, histidine, diaminobutyric acid, diaminopropionic acid, salts thereof, and/or combinations thereof. The amino acids in the oral care composition may generally be present in an L-shape or L-configuration. The amino acids may be provided in the form of salts of di-or tripeptides including amino acids. In at least one embodiment, at least a portion of the amino acids present in the oral care composition are in salt form. In preferred embodiments, the oral care composition comprises at least arginine (e.g., L-arginine) or an arginine source. Arginine may be provided as free arginine or a salt thereof. For example, arginine may be provided in the form of arginine phosphate, arginine hydrochloride, arginine sulfate, arginine bicarbonate, and the like, as well as mixtures or combinations thereof. The one or more amino acids may be provided in solution or in solid form. For example, one or more amino acids may be provided in aqueous solution. In preferred embodiments, the one or more amino acids comprise or are provided by an arginine bicarbonate solution.
The amount or concentration of one or more amino acids present in the oral care composition can vary widely. In at least one embodiment, the one or more amino acids may be present in an amount or concentration of from greater than 0% to about 20% by weight, based on the total weight of the oral care composition. For example, the one or more amino acids may be present in the oral care composition in an amount of greater than 0 wt%, about 2 wt%, about 4 wt%, about 6 wt%, about 8 wt%, or about 10 wt% to about 12 wt%, about 14 wt%, about 16 wt%, about 18 wt%, or about 20 wt%, based on the total weight of the oral care composition. In another example, the one or more amino acids can be present in the oral care composition in an amount of from greater than 0 wt% to about 20 wt%, from about 4 wt% to about 12 wt%, from about 6 wt% to about 10 wt%, or about 8 wt%, based on the total weight of the oral care composition. In preferred embodiments, the oral care composition comprises from about 6% to about 10% or about 8% by weight, based on the total weight of the oral care composition, and the amino acid may be provided from a solution. For example, the amino acid may be provided from an about 40% solution having one or more amino acids such as arginine.
Abrasive materials or abrasive systems
The oral care composition may include one or more abrasives or an abrasive system including one or more abrasives. As used herein, the term "abrasive" may also refer to materials commonly referred to as "polishing agents. Any orally acceptable abrasive can be used, but preferably the type, fineness (particle size) and amount of abrasive can be selected so that the enamel is not excessively abraded during normal use of the oral care composition.
The one or more abrasives can have a particle size or D50 of less than or equal to about 10 μm, less than or equal to about 8 μm, less than or equal to about 5 μm, or less than or equal to about 3 μm. The one or more abrasives can have a particle size or D50 of greater than or equal to about 0.01 μm, greater than or equal to about 0.05 μm, greater than or equal to about 0.1 μm, greater than or equal to about 0.5 μm, or greater than or equal to about 1 μm. Illustrative abrasives can include, but are not limited to, metaphosphate compounds, phosphates (e.g., insoluble phosphates) such as sodium metaphosphate, potassium metaphosphate, calcium pyrophosphate, magnesium orthophosphate, tricalcium phosphate, dicalcium phosphate dihydrate, dicalcium phosphate anhydrous, calcium carbonate (e.g., precipitated and/or natural calcium carbonate), magnesium carbonate, hydrated alumina, silica, zirconium silicate, aluminum silicate (including calcined aluminum silicate), polymethyl methacrylate, and the like, as well as mixtures or combinations thereof.
In a preferred embodiment, the oral care composition comprises at least calcium carbonate as an abrasive. In at least one embodiment, the precipitated calcium carbonate may be superior to natural calcium carbonate. While not intending to be bound by theory, it is believed that natural calcium carbonate has a relatively greater crystallinity or a relatively more crystalline structure than precipitated calcium carbonate, thereby making the calcium carbonate very hard. In contrast, precipitated calcium carbonate is relatively more amorphous and more brittle or brittle. Thus, precipitated calcium carbonate has relatively low abrasion resistance compared to natural calcium carbonate while maintaining sufficient cleaning power.
The one or more abrasives in the abrasive system can have a Pellicle Cleaning Rate (PCR) of greater than or equal to 80, greater than or equal to 82, greater than or equal to 84, greater than or equal to 86, greater than or equal to 88, greater than or equal to 90, greater than or equal to 92, greater than or equal to 94, greater than or equal to 96, greater than or equal to 98, greater than or equal to 100, greater than or equal to 102, greater than or equal to 104, greater than or equal to 106, greater than or equal to 108, greater than or equal to 110, greater than or equal to 112, or greater.
The amount or concentration of one or more abrasives present in the oral care composition can vary widely. In at least one embodiment, the amount or concentration of abrasive can be from greater than 0 wt% to about 60 wt%, based on the total weight of the oral care composition. For example, the abrasive can be present in the oral care composition in an amount of greater than 0 wt%, about 2 wt%, about 4 wt%, about 6 wt%, about 8 wt%, about 10 wt%, about 12 wt%, about 14 wt%, about 16 wt%, about 18 wt%, or about 19 wt% to about 21 wt%, about 22 wt%, about 24 wt%, about 26 wt%, about 28 wt%, about 30 wt%, about 32 wt%, about 34 wt%, about 36 wt%, about 38 wt%, or about 40 wt%. In another example, the abrasive can be present in the oral care composition in an amount from greater than 0 wt% to about 40 wt%, from about 2 wt% to about 38 wt%, from about 4 wt% to about 36 wt%, from about 6 wt% to about 34 wt%, from about 8 wt% to about 32 wt%, from about 10 wt% to about 30 wt%, from about 12 wt% to about 28 wt%, from about 14 wt% to about 26 wt%, from about 16 wt% to about 24 wt%, from about 18 wt% to about 22 wt%, or from about 19 wt% to about 21 wt%. In preferred embodiments, the abrasive may be present in the oral care composition in an amount of from about 25% to about 45% by weight, preferably from about 30% to about 40% by weight, or more preferably about 35% by weight, based on the total weight of the oral care composition.
Surfactants or foaming systems
The oral care composition may include one or more surfactants or foaming agents that are capable of or configured to provide relatively greater foam generation than conventional oral care compositions.
In at least one embodiment, the one or more surfactants or foaming agents may include at least one N-alkyl-N-acyl glucosamine. In another embodiment, the one or more surfactants or foaming agents may include at least one N-alkyl-N-acyl glucosamine and an additional surfactant. For example, the one or more surfactants or foaming agents may include at least one N-alkyl-N-acyl glucosamine as the active surfactant or foaming agent, and at least one additional surfactant or foaming agent. The additional surfactant or foaming agent may be an active surfactant or an inactive surfactant.
The N-alkyl-N-acyl glucamine can be represented by the formula (I),
wherein R is a Is straight-chain or branched, saturated or unsaturated C 6 -C 22 Alkyl, or alkyl or mono-or polyunsaturated alkenyl, and R b Is C 1 -C 4 An alkyl group. In a preferred embodiment, the N-alkyl-N-acyl glucosamine may be or include N-methyl-N-acyl glucosamine. For example, the one or more N-alkyl-N-acyl glucamines can be or include N-methyl-N-C 8 -C 10 -acyl glucamine and/or N-methyl-N-C 12 -C 14 -acyl glucamine. In at least one embodiment, the N-alkyl-N-acyl glucamine can be or includeWET (CAS number 1591782-62-5) and/or +.>DEG (CAS number 287735-50-6), each of which is commercially available from Clariant Corp. Of Charlotte, N.C..
The additional surfactant of the foaming agent may be or include, but is not limited to, one or more anionic surfactants, one or more nonionic surfactants, one or more cationic surfactants, one or more amphoteric surfactants, one or more zwitterionic surfactants, or a combination thereof.
The anionic surfactant may be or include, but is not limited to, water soluble salts of C8-20 alkyl sulfates, sulfonated monoglycerides of C8-20 fatty acids, sarcosinates, taurates, and the like. Illustrative anionic surfactants may also be or include, but are not limited to, sodium lauryl sulfate, sodium cocoyl monoglyceride sulfonate, sodium lauryl sarcosinate, sodium laureth sulfonate, sodium laureth carboxylate, sodium lauroyl methyltaurine, and sodium dodecylbenzenesulfonate. Additional illustrative anionic surfactants may be or include, but are not limited to, water soluble salts of higher fatty acid monoglyceride monosulfates, such as the sodium salt of monosulfated monoglycerides of hydrogenated coconut oil fatty acids, such as sodium N-methyl-N-alkyl taurate, sodium N-methyl-N-cocoyl taurate or sodium methyl cocoyl taurate, sodium cocoyl methyl taurate, sodium lauroyl methyl taurate, sodium cocoyl glyceride sulfate; higher alkyl sulfates such as sodium lauryl sulfate; higher alkyl-ether sulphates, e.g. of formula CH 3 (CH 2 ) m CH 2 (OCH 2 CH 2 ) n OSO 3 Higher alkyl-ether sulphates of X, wherein m is 6-16, e.g. 10, n is 1-6, e.g. 2, 3 or 4, and X is Na, e.g. sodium laureth-2 sulphate (CH 3 (CH 2 ) 10 CH 2 (OCH 2 CH 2 ) 2 OSO 3 Na); higher alkylaryl sulfonates such as sodium dodecyl benzene sulfonate (sodium laurylbenzene sulfonate); higher alkyl sulfoacetates, e.g. sodium lauryl sulfoacetate (sodium dodecyl sulfoacetate), 1, 2-dihydroxypropaneHigher fatty acid esters of alkanesulfonic acids, sulfolaurates (N-2-ethyl potassium sulfoacetamide) and sodium lauryl sarcosinate. As used herein, "higher alkyl" may refer to C 6 -C 30 An alkyl group. In at least one embodiment, the anionic surfactant may include one or more sodium N-methyl-N-alkyl taurates, such as sodium cocoyl methyl taurate, sodium lauroyl methyl taurate, and the like, and combinations thereof. When present, the anionic surfactant is present in an amount effective (e.g., greater than or equal to about 0.001 wt% of the formulation) but not at a concentration that will stimulate oral tissue (e.g., greater than or equal to about 1%), and the optimal concentration depends on the particular formulation and the particular surfactant.
In at least one preferred embodiment, the oral care composition comprises one or more N-methyl-N-acyl glucamines and at least one anionic surfactant. For example, the oral care composition includes one or more of N-methyl-N-acyl glucamine and sodium N-methyl-N-cocoyl taurate or sodium methyl cocoyl taurate.
In at least one embodiment, the anionic surfactant utilized in the oral care composition does not include sodium lauryl sulfate. For example, as further described herein, the oral care composition may be free or substantially free of sodium lauryl sulfate. As used herein, "free" or "substantially free" of a material may refer to a composition, component, or phase in which the material is present in an amount of less than 10.0 wt%, less than 5.0 wt%, less than 3.0 wt%, less than 1.0 wt%, less than 0.1 wt%, less than 0.05 wt%, less than 0.01 wt%, less than 0.005 wt%, or less than 0.0001 wt%, based on the total weight of the composition, component, or phase.
Amphoteric and zwitterionic surfactants can be or include, but are not limited to, C having anionic groups such as carboxylate, sulfate, sulfonate, phosphate, or phosphonate 8-20 Derivatives of aliphatic secondary and tertiary amines. Illustrative amphoteric and zwitterionic surfactants may include, but are not limited to, sulfobetaines and betaines, such as cocamidopropyl betaine (CAPB); fatDerivatives of aliphatic secondary and tertiary amines in which the aliphatic radical may be straight or branched chain and wherein one of the aliphatic substituents contains from about 8 to 18 carbon atoms and one contains an anionic water-solubilizing group (e.g., carboxylate, sulfonate, sulfate, phosphate, phosphonate, etc.); and combinations thereof. In at least one preferred embodiment, the oral care composition comprises one or more N-methyl-N-acyl glucamines and at least one amphoteric and/or zwitterionic surfactant. For example, the oral care composition includes one or more N-methyl-N-acyl glucamines and one or more betaines, such as cocamidopropyl betaine.
Illustrative nonionic surfactants may be or include, but are not limited to, octoxynol (e.g., polyethylene glycol tetramethylbutylphenyl ether, octylphenoxy polyethoxyethanol, or polyoxyethylene octylphenyl ether), such as octoxynol 1, 3, 5, 8, 9, 10, 12, 13, 16, 30, 40, 70, wherein the number indicates the number of repeating oxyethylene units or other octoxynol including a different number of oxyethylene repeating units in the side chain, sorbitan esters (e.g., generally under their trade names80 and60 sorbitan monooleate, sorbitan monostearate, etc.), polysorbates (e.g., commonly under their trade names +.>80、/>60、/>20 Polysorbate 80 (polyoxyethylene sorbitan monooleate), polysorbate 60 (polyoxyethylene sorbitan monostearate), polysorbate 20 #, known asPolyoxyethylene sorbitan monolaurate)), poloxamer (poloxamer) (a synthetic block polymer of ethylene oxide and propylene oxide, as commonly known under the trade name +.>Those known; for example->F127 or->F108 Or poloxamine (a synthetic block polymer of ethylene oxide and propylene oxide linked to ethylenediamine, such as is commonly under the trade name +. >Those known; for example->1508 or908, etc.), other nonionic surfactants such as +.>(having the formula CH 3 -(CH 2 ) 10-16 -(O-C 2 H 4 ) 1-25 Polyoxyethylene alkyl ether of-OH), -optionally, a polyoxyethylene alkyl ether of-OH>(stearic acid esterified with polyoxyethylene having 40-100 repeating oxyethylene units), and long chain fatty alcohols having a carbon chain of about 12 or more carbon atoms (e.g., about 12 to about 24 carbon atoms) (e.g., oleyl alcohol, stearyl alcohol, myristyl alcohol, docosahexaenoic alcohol, etc.). Additional nonionic surfactants may be or include, but are not limited to, polyethylene oxide condensates of alkyl phenols, products derived from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylenediamine, aliphatic alcoholsEthylene oxide condensates of (a), long chain tertiary amine oxides, long chain tertiary phosphine oxides, long chain dialkyl sulfoxides, and the like, or combinations thereof. In at least one embodiment, a nonionic surfactant may be generally defined as a compound produced by the condensation of an alkylene oxide group (hydrophilic in nature) with an organic hydrophobic compound that may be aliphatic or alkyl aromatic in nature.
In at least one embodiment, the oral care composition may be free or substantially free of one or more surfactants that are capable of or configured to react with one or more of the cationic or cationically charged ingredients/components of the oral care composition to form insoluble salts. For example, the oral care composition may be free or substantially free of one or more surfactants that are capable of or configured to react with one or more cationic or cationically charged amino acids (e.g., arginine). In another embodiment, the oral care composition may be free or substantially free of one or more surfactants that are capable of or configured to react with one or more cations provided or released by one or more ingredients/components of the oral care composition. For example, the oral care composition may be free or substantially free of one or more surfactants that are capable of or configured to react with one or more cations provided by one or more salts (e.g., inorganic salts) contained therein. For example, the oral care composition may be free or substantially free of one or more surfactants that are capable of or configured to react with one or more calcium ions provided by one or more abrasives of the oral care composition (e.g., calcium carbonate, etc.).
As discussed above, in at least one exemplary embodiment, the oral care composition may be free or substantially free of sodium lauryl sulfate or similar anionic surfactant. It will be appreciated that sodium lauryl sulfate and/or anionic surfactants similar thereto may be at least partially reacted with cationically charged species, such as partially cationically charged arginine and/or cations, for example, calcium ions from calcium carbonate, to form inorganic salts. It should be further appreciated that the reaction of sodium lauryl sulfate and/or an anionic surfactant similar thereto may reduce the availability and/or foaming capacity of sodium lauryl sulfate and/or an anionic surfactant similar thereto; and thus, reduces foaming of the oral care composition. Thus, in at least one exemplary embodiment, the oral care composition may be free or substantially free of sodium lauryl sulfate or similar anionic surfactant.
The amount of any one or more of the surfactants or foaming agents present in the oral care composition or components thereof (e.g., hydrophilic or hydrophobic phase) can vary widely. In at least one embodiment, the amount of any one or more of the surfactants or foaming agents present in the oral care composition or components thereof can be greater than 0.0 wt.% or 0.1 wt.% and less than or equal to 10.0 wt.% based on the total weight of the oral care composition or components thereof. For example, any one or more of the surfactants or foaming agents present in the oral care composition or components thereof may be present in an amount of about 0.5 wt%, about 1.0 wt%, about 1.5 wt%, about 2.0 wt%, or about 2.5 wt% to about 3.0 wt%, about 3.5 wt%, about 4.0 wt%, about 4.5 wt%, about 5.0 wt%, or about 10 wt%, based on the total weight of the oral care composition or components thereof. In another example, the amount of surfactant present in the oral care composition or component thereof can be from about 0.5 wt.% to about 5.0 wt.%, from about 1.0 wt.% to about 4.5 wt.%, from about 1.5 wt.% to about 4.0 wt.%, from about 2.0 wt.% to about 3.5 wt.%, or from about 2.5 wt.% to about 3.0 wt.%, based on the total weight of the oral care composition or component thereof. In exemplary embodiments, the amount of any one or more of the surfactants or foaming agents present in the oral care composition or components thereof may be from about 1% to about 2%, from about 1.25% to about 1.75%, or about 1.5% by weight, based on the total weight of the oral care composition.
Fluoride ion source
In at least one embodiment, the oral care composition can be free or substantially free of fluoride (e.g., soluble fluoride salts). In at least one embodiment, the oral care composition can include a fluoride, such as one or more fluoride ion sources (e.g., soluble fluoride salts). A variety of fluoride ion generating materials may be employed as the soluble fluoride source. Examples of suitable fluoride ion generating materials can be found in U.S. Pat. No. 3,535,421 to Briner et al, U.S. Pat. No. 4,885,155 to Parran et al, and U.S. Pat. No. 3,678,154 to Widder et al, the disclosures of which are incorporated herein by reference. Illustrative fluoride ion sources include, but are not limited to, fluoride, stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, fluorosilicates such as sodium and ammonium fluorosilicates, amine fluoride, ammonium fluoride, and combinations thereof. In typical embodiments, the fluoride ion source comprises sodium monofluorophosphate. The amount of fluoride ion source in the oral care composition can be greater than 0 wt.% and less than 0.8 wt.%, less than 0.7 wt.%, less than 0.6 wt.%, less than 0.5 wt.%, or less than 0.4 wt.%. The fluoride ion source may be present in an amount sufficient to provide a total of about 100 to about 20,000ppm, about 200 to about 5,000ppm, or about 500 to about 2,500ppm of fluoride ions.
Orally acceptable vehicle or carrier
The oral care composition may form at least a portion of or be used in one or more oral care products. The oral care composition may include or be combined with an orally acceptable vehicle. For example, the oral care composition can include or be combined with an orally acceptable vehicle to form an oral care product. The orally acceptable vehicle can comprise any known ingredients or additives. The orally acceptable vehicle can include various dentifrice ingredients to adjust the rheology and mouthfeel of the oral care composition.
In at least one embodiment, the orally acceptable vehicle can include one or more humectants. Illustrative humectants can be or include, but are not limited to, glycerin, propylene glycol, polyethylene glycol, and combinations thereof. In a preferred embodiment, the orally acceptable vehicle may be or include, but is not limited to, propylene glycol.
In at least one embodiment, the orally acceptable vehicle can include an orally acceptable solvent. Illustrative solvents may include, but are not limited to, one or more of the following: ethanol, methanol, isopropanol, butanol, water, acetone, methyl ethyl ketone, ethyl acetate, butyl acetate, cyclohexanone, cyclohexane, methylene chloride, chloroform, carbon tetrachloride, trichloroethylene, perchloroethylene, methyl glycol acetate, toluene, benzene, diethyl ether and benzyl alcohol. In a preferred embodiment, the orally acceptable solvent comprises benzyl alcohol.
The orally acceptable vehicle can be present in an amount of from 5% to about 60% by weight, based on the total weight of the oral care composition. For example, the orally acceptable vehicle can be present in an amount of about 5%, about 10%, about 15%, or about 20% to about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, or about 60% by weight. In another example, the orally acceptable vehicle can be present in an amount from about 5% to about 60%, from about 10% to about 55%, from about 15% to about 50%, from about 20% to about 25%, from about 20% to about 40%, from about 20% to about 35%, from about 20% to about 30%, or from about 20% to about 25% by weight. In exemplary embodiments, the orally acceptable vehicle can be present in an amount of about 20% to about 30% by weight, preferably about 20% to about 25% by weight, and more preferably about 22% to about 25% by weight. In preferred embodiments, the orally acceptable vehicle can be present in an amount of about 22% to about 25% by weight, or about 23% by weight.
Thickening system and/or viscosity control agent
The oral care product or oral care composition thereof may include a thickening system having one or more thickening agents. The one or more thickening agents may be any orally acceptable thickening agent or thickening agent configured to control the viscosity of the oral care product or oral care composition thereof. Illustrative thickeningThe agent may be or include, but is not limited to, colloidal silica, fumed silica, crosslinked polyvinylpyrrolidone (PVP) polymer, crosslinked polyvinylpyrrolidone (PVP), and the like, and mixtures or combinations thereof. In at least one embodiment, the thickening system comprises a crosslinked polyvinylpyrrolidone (PVP) polymer. The thickening system may also include a thickening system commercially available from Ashland inc (Covington, KY)XL 10F. Illustrative thickeners may also be or include, but are not limited to carbomers (e.g., carboxyvinyl polymers), carrageenans (e.g., irish moss, carrageenan, iota-carrageenan, etc.), high molecular weight polyethylene glycols (e.g., midland, mich., midland, MI.) of the Dow chemical company (Dow Chemical Company) >) Cellulose polymers, hydroxyethyl cellulose, carboxymethyl cellulose and salts thereof (e.g., sodium CMC), natural gums (e.g., karaya gum, xanthan gum, gum arabic, and tragacanth gum), colloidal magnesium aluminum silicate and the like, and mixtures or combinations thereof.
In more typical embodiments, the thickening system may comprise an organic polymer, which may also be configured as an adhesion enhancer. Illustrative organic polymers may be or include, but are not limited to, hydrophilic polymers such as carbomers, e.g., carboxymethylene polymers, e.g., acrylic acid polymers and acrylic acid copolymers. Carboxypolymethylene is a slightly acidic vinyl polymer having reactive carboxyl groups. In typical embodiments, the thickening system comprises carboxypolymethylene, e.g974 and/or 980 commercially available from Noveon, inc.
In at least one embodiment, the thickening system may comprise a single thickener. For example, the thickening system may comprise a crosslinked polyethylenePyrrolidone (PVP) polymers or organic polymers (e.g). In another embodiment, the thickening system may include a plurality of thickening agents. For example, the thickening system may include a crosslinked PVP polymer and an organic polymer.
The amount or concentration of thickening system and/or thickening agent thereof present in the oral care composition can vary widely. The thickening system and/or thickening agent thereof may be present in the oral care composition in an amount of from about 1.0 wt% to about 3.0 wt% based on the total weight of the oral care composition. For example, the thickening system and/or thickening agent thereof can be present in the oral care composition in an amount of about 1 wt%, about 1.1 wt%, about 1.2 wt%, about 1.3 wt%, about 1.4 wt%, about 1.5 wt%, about 1.6 wt%, about 1.7 wt%, about 1.8 wt%, about 1.9 wt%, about 2.0 wt%, or about 2.1 wt% to about 2.2 wt%, about 2.3 wt%, about 2.4 wt%, about 2.5 wt%, about 2.6 wt%, about 2.7 wt%, about 2.8 wt%, about 2.9 wt%, or about 3.0 wt%. In another example, the thickening system and/or thickening agent thereof can be present in the oral care composition in an amount from about 1.2 wt% to about 3.0 wt%, from about 1.3 wt% to about 2.9 wt%, from about 1.4 wt% to about 2.8 wt%, from about 1.5 wt% to about 2.7 wt%, from about 1.6 wt% to about 2.6 wt%, from about 1.7 wt% to about 2.5 wt%, from about 1.8 wt% to about 2.4 wt%, from about 1.9 wt% to about 2.3 wt%, or from about 2.0 wt% to about 2.2 wt%. In typical embodiments, the thickening system and/or thickening agent thereof may be present in the oral care composition in an amount of from about 1.0 wt% to about 2.0 wt%, more typically from about 1.2 wt% to about 1.8 wt%, and more typically about 1.5 wt%.
PH regulator
The oral care product or oral care composition or components thereof may include one or more pH adjusting agents. For example, the oral care composition may include one or more acidulants and/or one or more alkalizing agents configured to reduce and/or increase, respectively, the pH thereof. Illustrative acidulants and/or one or more alkalizing agents can be or include, but are not limited to, alkali metal hydroxides such as sodium hydroxide and/or potassium hydroxide, citric acid, hydrochloric acid, and the like, or combinations thereof.
The oral care composition or components thereof may also include one or more buffers configured to control or adjust the pH within a predetermined or desired range. Illustrative buffers can include, but are not limited to, sodium bicarbonate, sodium phosphate, sodium carbonate, sodium acid pyrophosphate, sodium citrate, and mixtures thereof. The sodium phosphate may include sodium dihydrogen phosphate (NaH) 2 PO 4 ) Disodium hydrogen phosphate (Na) 2 HPO 4 ) Trisodium phosphate (Na) 3 PO 4 ) And mixtures thereof. In typical embodiments, the buffer may be anhydrous disodium hydrogen phosphate or disodium hydrogen phosphate and/or sodium dihydrogen phosphate. In another embodiment, the buffer comprises anhydrous disodium hydrogen phosphate or disodium hydrogen phosphate and phosphoric acid (e.g., syrup-like phosphoric acid; 85% -food grade).
In at least one embodiment, an acidifying, buffering, and/or buffering agent may be included in the oral care composition or components thereof to provide a generally neutral pH or an orally acceptable pH range. In another embodiment, an acidifying, buffering, and/or buffering agent may be included in the oral care composition or component thereof (e.g., hydrophobic phase and/or hydrophilic phase), wherein the pH is between 2 and 10, 2 and 8, 3 and 9, 4 and 8, 6 and 10, or 7 and 9. Any additional orally acceptable pH adjusting agent can be used, including, but not limited to, carboxylic acids, phosphoric and sulfonic acids, acid salts (e.g., monosodium citrate, disodium citrate, monosodium malate, etc.), alkali metal hydroxides such as sodium hydroxide, carbonates such as sodium carbonate, bicarbonate, sesquicarbonate, borates, silicates, phosphates (e.g., monosodium phosphate, trisodium phosphate, pyrophosphates, etc.), imidazoles, and mixtures thereof. The one or more pH adjusting agents may optionally be present in an amount effective to maintain the oral care composition or components thereof within an orally acceptable pH range.
Flavoring agent
The oral care product and/or oral care composition thereof may also include one or more flavoring agents. Illustrative flavoring agents may include, but are not limited to, essential oils and various flavoring aldehydes, esters, alcohols, and the like. Flavoring agents may also include, but are not limited to, sweeteners, sucralose, dextrose, polydextrose, sucrose, maltose, dextrin, dried invert sugar, mannose, xylose, ribose, fructose, levulose, galactose, corn syrup (including high fructose corn syrup and corn syrup solids), partially hydrolyzed starch, hydrogenated starch hydrolysates, sorbitol, mannitol, xylitol, maltitol, isomalt, aspartame, neotame, saccharin and salts thereof (e.g., sodium saccharin), dipeptide-based intense sweeteners, cyclamates, dihydrochalcones, and mixtures thereof. Examples of essential oils include essential oils of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, marjoram, cinnamon, lemon, lime, grapefruit, and orange. In another example, the flavoring agents may include menthol, carvone, and anethole. In typical embodiments, the flavoring agents include peppermint and spearmint. In a more typical embodiment, the flavoring includes a Firmenich Newman flavoring. The amount of flavoring in the oral care product and/or its oral care composition can be less than 1.0wt%, less than 0.9wt%, less than 0.8wt%, or less than 0.7wt%. For example, the amount of flavoring agent in the oral care product and/or oral care composition thereof can be from about 0.0wt% to about 1.0wt%, from about 0.5wt% to about 0.9wt%, from about 0.7wt% to about 0.8wt%. In typical embodiments, the amount of flavoring in the oral care product and/or oral care composition thereof is from about 0.55wt% to about 0.70wt%.
Additional ingredients
It will be appreciated by those of ordinary skill in the art that the oral care product and/or oral care composition thereof may include other additional ingredients/components. For example, the oral care product and/or oral care composition thereof may include anticaries agents, desensitizing agents, viscosity modifiers, diluents, pH modifying agents, humectants, mouth feel agents, sweeteners, flavoring agents, colorants, preservatives, and the like, as well as combinations and mixtures thereof. It will also be appreciated by those of ordinary skill in the art that while the general properties of each of the above-mentioned classes of materials may be different, some common properties may also exist and any given material may be used for multiple purposes in two or more of these classes of materials.
In at least one embodiment, the additional ingredients/components may include one or more active materials configured to prevent and/or treat one or more conditions and/or disorders of the oral cavity. For example, the one or more active materials may be configured to prevent and/or treat one or more conditions and/or disorders of hard and/or soft tissues of the oral cavity. The active material may also be configured to prevent and/or treat one or more physiological disorders and/or conditions, and/or provide a beautification benefit to the oral cavity.
In at least one embodiment, the oral care product or oral care composition thereof may include an anticalculus agent. Illustrative anticalculus agents may include, but are not limited to, phosphates and polyphosphates (e.g., pyrophosphates), polyaminopropane sulfonic Acid (AMPS), hexametaphosphate, zinc citrate trihydrate, polypeptides, polyolefin sulfonates, polyolefin phosphates, bisphosphonates. In typical embodiments, the anticalculus agent comprises tetrasodium pyrophosphate (TSPP), sodium Tripolyphosphate (STPP), or a combination thereof.
The oral care product or oral care composition thereof may include an antioxidant. Any orally acceptable antioxidant may be used, including but not limited to: butylated Hydroxyanisole (BHA), butylated Hydroxytoluene (BHT), vitamin a, carotenoids, vitamin E, flavonoids, polyphenols, ascorbic acid, herbal antioxidants, chlorophyll, melatonin, and the like, and combinations and mixtures thereof.
The oral care composition may include zinc. The zinc of the oral care composition may be or include zinc ions and/or one or more zinc salts. For example, zinc salts may at least partially dissociate in aqueous solutions to produce zinc ions. Illustrative zinc salts may include, but are not limited to, zinc lactate, zinc oxide, zinc chloride, zinc phosphate, zinc citrate, zinc acetate, zinc borate, zinc butyrate, zinc carbonate, zinc formate, zinc gluconate, zinc glycerate, zinc glycolate, zinc oxide, zinc phosphate, zinc picolinate, zinc propionate, zinc salicylate, zinc silicate, zinc stearate, zinc tartrate, zinc undecenoate, and mixtures thereof. In a preferred embodiment, the zinc salt is zinc lactate.
The oral care composition may include one or more pigments, such as whitening pigments. In some embodiments, the whitening pigment comprises particles ranging in size from about 0.1 μm to about 10 μm and having a refractive index greater than about 1.2. Suitable whitening agents include, but are not limited to, titanium dioxide particles, zinc oxide particles, aluminum oxide particles, tin oxide particles, calcium oxide particles, magnesium oxide particles, barium oxide particles, silicon dioxide particles, zirconium silicate particles, mica particles, talc particles, tetra calcium phosphate particles, amorphous calcium phosphate particles, alpha tricalcium phosphate particles, beta tricalcium phosphate particles, hydroxyapatite particles, calcium carbonate particles, zinc phosphate particles, silicon dioxide particles, zirconium silicate particles, and combinations thereof. The amount of whitening pigment, such as titanium dioxide particles, may be sufficient to whiten teeth.
Method
The present disclosure may provide methods for treating dentinal hypersensitivity and/or cleaning teeth in a human or animal subject using an oral care product and/or oral care composition thereof. As used herein, an "animal subject" may include higher non-human mammals, such as canines, felines, and equines. The method may comprise contacting the oral care product and/or oral care composition thereof with water. The method may further comprise contacting the tooth surface with an oral care product and/or an oral care composition thereof. Contacting the tooth surface with the oral care product and/or oral care composition thereof may include placing the oral care composition (e.g., toothpaste) on a toothbrush and brushing the teeth with the toothbrush.
The oral care product and/or oral care composition thereof may be applied at predetermined intervals and/or contacted with the tooth surface. For example, on a daily basis, at least once a day, two or more times a day for a plurality of days, or alternatively every other day. In another example, the oral care product and/or whitening composition thereof may be applied and/or contacted with the tooth surface at least once a day, at least once every two days, at least once every three days, at least once every five days, at least once a week, at least once every two weeks, or at least once a month. The oral care products and/or oral care compositions thereof may be utilized for up to 2 weeks, up to 3 weeks, up to 4 weeks, up to 6 weeks, up to 8 weeks, or longer.
The present disclosure may also provide methods for preparing oral care compositions having increased foam generation as compared to conventional oral care compositions. The method may comprise combining or contacting an orally acceptable vehicle with at least one N-alkyl-N-acyl glucosamine and optionally at least one additional surfactant or foaming agent. The method may further comprise combining an orally acceptable vehicle and at least one N-alkyl-N-acyl glucosamine with one or more amino acids and one or more abrasives. For example, the method can include combining an orally acceptable vehicle and at least one N-alkyl-N-acyl glucosamine with arginine or a source of arginine and calcium carbonate.
All ingredients used in the compositions described herein should be orally acceptable. As used herein, "orally acceptable" may refer to any ingredient present in a composition as described in an amount and in a form that does not render the composition unsafe for use in the oral cavity.
Examples
The examples and other embodiments described herein are exemplary and are not intended to limit the full scope of the compositions and methods described herein. Equivalent changes, modifications and variations of specific embodiments, materials, compositions and methods may be made within the scope of the present disclosure, with substantially similar results.
Example 1
The efficacy of different oral care compositions to generate foam was evaluated. Specifically, control toothpaste composition (C) and six exemplary or test toothpaste compositions (1) - (6) were prepared by combining the ingredients/components of the base toothpaste compositions indicated in table 1 with the corresponding surfactants indicated in table 2. The components were mixed for about 10 minutes under mechanical agitation to prepare each of toothpaste compositions (C) and (1) - (6).
TABLE 1
Base toothpaste composition
TABLE 2
Surfactants were added to the base dentifrice compositions to prepare control dentifrice compositions (C) and exemplary dentifrice compositions (1) - (6)
To evaluate the efficacy of foam generation, a kruss dynamic foam analyzer (DFA 100) commercially available from kruss GmbH, hamburg, germany, was used. The kruss dynamic foam analyzer was adjusted according to the parameters/test conditions indicated in table 3.
TABLE 3 Table 3
Parameters of Kruss dynamic foam analyzer
Parameters (parameters) Test conditions
Sample concentration 30％
Stirring speed 5,000 RPM
Interval of oscillation 6 seconds
Foam time 60 seconds
Delay time 450 seconds
The results of foam generation are summarized in table 4.
TABLE 4 Table 4
Summary of foam Generation in control toothpaste compositions (C) and exemplary toothpaste compositions (1) - (6)
As indicated in table 4, all toothpaste compositions (1) - (6) comprising either glucamide-8 or glucamide-12 exhibited relatively greater foam generation than the control toothpaste composition (C). This finding is both surprising and unexpected because all toothpaste compositions (1) - (6) included relatively lower active foaming agents (i.e., glucamide-8 or glucamide-12) as compared to control toothpaste composition (C). It was further observed that the foam generated or produced in toothpaste compositions (1) - (6) comprising either glucamide-8 or glucamide-12 was relatively denser, richer or more creamy when compared to control toothpaste composition (C).
The present disclosure has been described with reference to exemplary embodiments. While a limited number of embodiments have been shown and described, it will be appreciated by those skilled in the art that changes may be made in these embodiments without departing from the principles and spirit of the preceding embodiments. The disclosure is intended to be interpreted as including all such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.

Claims (14)

1. An oral care composition comprising:
an orally acceptable vehicle;
an amino acid, wherein the amino acid comprises arginine;
N-alkyl-N-acyl glucosamine surfactants, wherein the N-alkyl-N-acyl glucosamine comprises N-methyl-N-C 8 -C 10 -acyl glucamine, N-methyl-N-C 12 -C 14 -acyl glucamine or a combination thereof; and
an anionic surfactant or a zwitterionic surfactant, wherein the anionic surfactant comprises sodium N-methyl-N-alkyl taurate and the zwitterionic surfactant comprises cocamidopropyl betaine; and is also provided with
Wherein the oral care composition comprises less than 0.01% by weight sodium lauryl sulfate.
2. The oral care composition of claim 1, wherein the arginine is provided by arginine bicarbonate or by an arginine bicarbonate solution.
3. The oral care composition of any preceding claim, further comprising an abrasive.
4. The oral care composition of claim 3, wherein the abrasive comprises one or more of: sodium metaphosphate, potassium metaphosphate, calcium pyrophosphate, magnesium orthophosphate, tricalcium phosphate, dicalcium phosphate dihydrate, anhydrous dicalcium phosphate, calcium carbonate, magnesium carbonate, hydrated alumina, silica, zirconium silicate, aluminum silicate, polymethyl methacrylate or combinations thereof.
5. The oral care composition of claim 4, wherein the aluminum silicate is a calcined aluminum silicate.
6. The oral care composition of claim 4 or 5, wherein the abrasive comprises calcium carbonate.
7. The oral care composition of claim 6, wherein the calcium carbonate comprises natural calcium carbonate or precipitated calcium carbonate.
8. The oral care composition of any preceding claim, further comprising one or more anionic surfactants, one or more nonionic surfactants, one or more cationic surfactants, one or more amphoteric surfactants, or a combination thereof.
9. The oral care composition of claim 1, wherein the sodium N-methyl-N-alkyl taurate comprises sodium cocoyl methyl taurate and sodium lauroyl methyl taurate.
10. The oral care composition of any preceding claim, wherein the zwitterionic surfactant further comprises a sulfobetaine.
11. The oral care composition of any preceding claim, wherein the oral care composition is a toothpaste.
12. The oral care composition according to any one of claims 1 to 11 for use in the treatment or alleviation of dentinal hypersensitivity.
13. A method for preparing an oral care composition with increased foam generation, the method comprising combining an orally acceptable vehicle with at least one N-alkyl-N-acyl glucosamine, an anionic surfactant or a zwitterionic surfactant, and an amino acid, wherein the N-alkyl-N-acyl glucosamine comprises N-methyl-N-C 8 -C 10 -acyl glucamine, N-methyl-N-C 12 -C 14 -acyl glucamine or a combination thereof, the anionic surfactant comprising N-methyl-N-alkyl taurinesSodium acid, the zwitterionic surfactant comprising cocamidopropyl betaine and the amino acid comprising arginine, wherein the oral care composition comprises less than 0.01% by weight sodium lauryl sulfate.
14. The method of claim 13, further comprising adding one or more abrasives to the orally acceptable vehicle and the at least one N-alkyl-N-acyl glucosamine.
CN201880098740.XA 2018-11-02 2018-11-02 Oral care compositions comprising N-alkyl-N-acyl glucamines Active CN112867480B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/058936 WO2020091805A1 (en) 2018-11-02 2018-11-02 Oral care compositions comprising n-alkyl-n-acylglucamines

Publications (2)

Publication Number Publication Date
CN112867480A CN112867480A (en) 2021-05-28
CN112867480B true CN112867480B (en) 2024-03-26

Family

ID=64607300

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880098740.XA Active CN112867480B (en) 2018-11-02 2018-11-02 Oral care compositions comprising N-alkyl-N-acyl glucamines

Country Status (8)

Country Link
EP (1) EP3856135A1 (en)
CN (1) CN112867480B (en)
AU (1) AU2018448003B2 (en)
BR (1) BR112021007596B1 (en)
CA (1) CA3117941C (en)
MX (1) MX2021004787A (en)
WO (1) WO2020091805A1 (en)
ZA (1) ZA202101942B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4301323A1 (en) 2021-03-05 2024-01-10 Unilever IP Holdings B.V. Oral care composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023582A1 (en) * 1994-03-02 1995-09-08 Henkel Kommanditgesellschaft Auf Aktien Mouth and dental care agents
WO2017205230A1 (en) * 2016-05-26 2017-11-30 3M Innovative Properties Company Therapeutic dental pastes and related methods and kits

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678154A (en) 1968-07-01 1972-07-18 Procter & Gamble Oral compositions for calculus retardation
US3535421A (en) 1968-07-11 1970-10-20 Procter & Gamble Oral compositions for calculus retardation
US4885155A (en) 1982-06-22 1989-12-05 The Procter & Gamble Company Anticalculus compositions using pyrophosphate salt
US6436370B1 (en) * 1999-06-23 2002-08-20 The Research Foundation Of State University Of New York Dental anti-hypersensitivity composition and method
CN107106447B (en) * 2014-12-26 2021-01-22 高露洁-棕榄公司 Oral care compositions and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023582A1 (en) * 1994-03-02 1995-09-08 Henkel Kommanditgesellschaft Auf Aktien Mouth and dental care agents
WO2017205230A1 (en) * 2016-05-26 2017-11-30 3M Innovative Properties Company Therapeutic dental pastes and related methods and kits

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Self-assembly, hydration, and structures in N-decanoyl-N-methylglucamide aqueous solutions: Effect of salt addition and temperature;J.A.Molina-Bolívar,et al.;《Journal of Colloid and Interface Science》;20070501;第313卷;第656页摘要部分,第657-658页第2.1-2.2节内容 *

Also Published As

Publication number Publication date
BR112021007596A2 (en) 2021-07-27
AU2018448003B2 (en) 2021-09-23
BR112021007596B1 (en) 2024-02-20
ZA202101942B (en) 2023-09-27
WO2020091805A1 (en) 2020-05-07
CA3117941C (en) 2022-10-11
CA3117941A1 (en) 2020-05-07
MX2021004787A (en) 2021-06-08
CN112867480A (en) 2021-05-28
AU2018448003A1 (en) 2021-05-06
EP3856135A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
AU2019200760B2 (en) Oral care compositions and methods of use
CN110099721A (en) Oral care composition and application method
CN112867480B (en) Oral care compositions comprising N-alkyl-N-acyl glucamines
US10736830B2 (en) Oral care compositions and methods for the same
WO2021041515A1 (en) Oral care compositions having increased foam production and methods for the same
CN113226276B (en) Oral care compositions and methods therefor
US11633337B2 (en) Oral care compositions and methods for the same
US20210196588A1 (en) Oral Care Compositions and Methods of Use
CN114025734A (en) Oral care compositions and methods of use
AU2021338260B2 (en) Oral care compositions
US20230346660A1 (en) Oral Care Compositions
US20220323319A1 (en) Oral care compositions
CN117320683A (en) Oral care compositions
BR112021011880B1 (en) ORAL HYGIENE COMPOSITION AND USE OF THE SAME
CN113967173A (en) Oral care compositions comprising sodium lauroyl sarcosinate and betaine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant